国际病理科学与临床杂志2012，Vol.32Issue(2)：150-153,4.DOI:10.3969/j.issn.1672-7347.2012.02.012
ERCC1在非小细胞肺癌个体化治疗中的研究进展
Progression of ERCC1 in customizing chemotherapy of non-small cell lung cancer
摘要
Abstract
Nowadays, lung cancer remains the leading cause of cancer-related death, as well as being characterized by great morbidity. Treating patients with non-small cell lung cancer (NSCLC) is a daunting task, but during recent years new options have emerged. Platinum-based doublets remain the cornerstone of chemotherapy in non-small cell llung cancer, though it achieves a response rate only in the range from 20% to 40%. Biomarkers such as ERCC1 are widely investigated and have shown good perspective. By tailoring treatment guided by biomarkers, it is now possible to improve outcome and maintain stable quality of life. In the future, biomarkers need optimization of methodology and prospective validation before clinical implementation.关键词
ERCC1/非小细胞肺癌/个体化治疗Key words
ERCC1/ non-small cell lung cancer/ customizing chemotherapy引用本文复制引用
陈佳,谭清和..ERCC1在非小细胞肺癌个体化治疗中的研究进展[J].国际病理科学与临床杂志,2012,32(2):150-153,4.基金项目
江苏省卫生厅面上项目(H200867). （H200867）
